Human Anti-rabies Vaccine Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH2879 | Last Updated On: Jun 25 2022 | Available Formats

> Global Human Anti-rabies Vaccine Market Expected to reach a high CAGR of 5% during the forecast period 2022-2029: DataM Intelligence

Global Human Anti-rabies Vaccine Market is segmented By Product Type (Vero Cell Rabies Vaccine, Baby Hamster Kidney (BHK) Cells, Chick Embryo Cell Rabies Vaccine, Others), By Usage (Post-Exposure Prophylaxis (PEP), Pre-Exposure Vaccination (PEV)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Market Overview

Global Human Anti rabies Vaccine Market is expected to grow at a CAGR of 5% during the forecast period (2022-2029)

Rabies is a zoonotic disease (a disease that is transmitted from animals to humans), caused by the rabies virus. Rabies is a virus that is usually spread by the bite or scratch of an animal.

Domestic dogs are the most common reservoir of the virus, with more than 99% of human deaths caused by dog-mediated rabies. The virus is transmitted in the saliva of rabid animals and generally enters the body via infiltration of virus-laden saliva from a rabid animal into a wound or by direct exposure of mucosal surfaces to saliva from an infected. Rabies is a 100% vaccine-preventable disease.

Global health organizations have taken collective action to control the rabies virus. For instance, in 2015, WHO, Food and Agriculture Organization (FAO), International Organization for Animal Health (OIE) and the Global Alliance for Rabies Control (GARC) came together to adopt a common strategy to achieve “Zero human Rabies deaths by 2030” and formed the United Against Rabies collaboration

Segmentation Analysis:-

The global human anti-rabies vaccine is segmented based on usage, which pre-exposure prophylaxis and post-exposure prophylaxis.

Post-exposure prophylaxis holds the major market share in 2018 and it is expected to remain dominant over the forecast period. Increasing cases of rabies will increase the demand for post-exposure prophylaxis vaccines in the future. For instance, according to the Food and Drug Administration (FDA), in the United States, about 60,000 individuals are treated with post-exposure prophylaxis on an annual basis.

By Product Type,

The Purified Chick Embryo Cell Rabies Vaccine is Expected to Grow at Significant Growth Rate

The purified chick embryo cell vaccine protects people from post-exposure or pre-exposure. The veterinarians who are in contact with animals, such as dogs, cats, foxes, skunks, raccoons, bobcats, coyotes, and bats are more likely to be exposed to the rabies virus, which leads to an increased number of rabies cases. Purified chick embryo cell rabies vaccines are prepared by primary chick embryo cells derived from specific pathogen-free (SPF) eggs. It consists of purified and concentrated rabies virus antigen, inactivated with B-propiolactone. It acts by exposing a small dose of the rabies virus to the patient to develop immunity to the disease. This vaccine can be used for post-exposure or pre-exposure

Geographical Analysis:-

North America is dominating the Animal Anti-rabies Vaccine market in 2018, and it is expected to remain dominant over the forecast period, due to increasing approval of rabies vaccine in this region. The U.S. is expected to have a high rate of Canine bites, a major cause of 98% of human rabies deaths worldwide. The U.S. successfully eliminated the canine rabies virus. On 11th November 2019, Mexico has become the first country in the world to receive validation from the World Health Organization (WHO) for eliminating dog-transmitted rabies as a public health problem.

Asia-Pacific is expected to grow at a higher pace over the forecast period due to the increase in cases of rabies which will increase the requirement of rabies vaccines. For instance, according to WHO, in Asian countries an estimated 35, 172 human deaths per year due to rabies.

In addition, active involvement by manufacturers in such as China, Japan and India towards the development of innovative rabies vaccines and their substitutes is driving the growth in this region. For instance, in February 2018, BioNote, Inc., a South Korean veterinary diagnostic company operating in rabies diagnostics, introduced a new immune-fluorescent device, Vcheck, which can measure diagnostic result values with the help of fluorescent materials which help in detecting the zoonotic disease in animals.

Some of the major players operating in the Asia-Pacific region are Yisheng Biopharma, Serum Institute of India, Zuventus, and Bharat Biotech Ltd. Moreover companies such as Yisheng Laboratories and CPL Laboratories (India) have vaccine candidates in clinical trials

Key Developments:-

Global Strategic Plan to End Human Deaths from Dog-mediated Rabies by 2030: The WHO leads the collective “United Against Rabies” to drive progress towards "Zero human deaths from dog-mediated rabies by 2030”

Phase 1 began in 2018, targeting 29 countries that provide regional cases of success. In phase 2, 52 more countries will be encouraged to commit to rabies elimination; and, in phase 3, all other countries in which rabies is endemic will be invited to commit to the Strategic Plan.

In 2015, in response to an international call to set the goal of zero human dog-mediated rabies deaths worldwide by 2030, the World Health Organization (WHO), the World Organization for Animal Health (OIE), the Food and Agriculture Organization of the United Nations (FAO) and the Global Alliance for Rabies Control (GARC) joined forces in the United Against Rabies collaboration (UAR) to achieve this goal.

In 2019 Gavi has included human rabies vaccines in its vaccine investment strategy 2021-2025 which will support scaling up rabies PEP in Gavi eligible countries, WHO will continue to advise on best strategies and practices for its rollout to countries requesting rabies vaccine.

Rising incidences of animal bites are one of the major driving factors leading to the growth of the human anti-rabies vaccine market.

➢ Animal bites are the major cause of rabies in humans. Rabies is a significant health concern following dog bites, cat bites and monkey bites. Dogs are the main source of human rabies deaths, contributing up to 99% of all rabies transmissions to humans.

➢ For instance, According to the Center for Disease Control (CDC), approximately 4.7 million dog bites occur in the United States each year, and 800,000 of those bites result in medical care.

➢ According to the World Health Organization (WHO), rabies kills about 60 000 people a year, of whom over 40% are children under 15, mainly in rural areas of economically disadvantaged countries in Africa and Asia.

➢ Of all human cases, up to 99% are acquired from the bite of an infected dog.

➢ The estimated cost of rabies is approximately US$ 8.6 billion per year, of which 54% is for productivity losses due to premature deaths, 37% is for treatment of humans bitten by dogs suspected of being rabid and only 2% is spent on dog vaccination and population control.

Trending Topics

Animal Anti-rabies Vaccine Market

Anthrax Vaccines Market

Meningitis Vaccines Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!